BioVaxys Technology Corp.
BVAXF · OTC
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.01 | -0.03 | -0.05 |
| FCF Yield | -20.08% | -52.48% | -7.74% | -17.21% |
| EV / EBITDA | 0.00 | 0.00 | 0.00 | -4.70 |
| Quality | ||||
| ROIC | 168.58% | 71.25% | 491.61% | -73.13% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.47 | 0.14 | 0.13 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -176.68% | 33.01% | 70.26% | -331.53% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.09 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |